DHEA Menopause 21-RCT Meta-Analysis: 50 mg/Day+ Increases Estradiol with Pronounced Effect in 60+
WELLNESS

DHEA Menopause 21-RCT Meta-Analysis: 50 mg/Day+ Increases Estradiol with Pronounced Effect in 60+

By Polly · · https://academic.oup.com/jsm/article/21/Supplement_2/qdae002.236/7618265
KO | EN

A 21-RCT meta-analysis comprehensively examining DHEA (dehydroepiandrosterone), a postmenopausal hormone support option, was published. DHEA 50 mg/day or higher meaningfully increases estradiol in postmenopausal adults, with more pronounced effect in 60+ population.

Meta-analysis core results

Participants: 21 RCTs.

Estradiol increase: 50 mg/day+ DHEA meaningfully increases.

60+ effect: More pronounced estradiol changes in 60+ population.

Below 50 mg/day: No meaningful change. 50+ mg/day needed for clinical effect.

Symptom effect limit: Whether hormonal changes translate to clinical symptom relief is a separate question. Data unclear.

6-month trial data

Participants: 42 early menopause symptomatic adults.

Intervention: Oral DHEA 50 mg/day or placebo. 6 months.

Core results:

  • Meaningful effects on hormone profile
  • Some menopausal physical symptom improvement
  • Some sexual function improvement
  • Some psycho-emotional parameter improvement

Interpretation: DHEA possible adjunct option for menopausal symptoms. But larger trials needed.

What is DHEA

DHEA (dehydroepiandrosterone): Steroid hormone synthesized in adrenal glands. Precursor to estrogens and androgens.

Natural changes: Peak in 20s, declining with aging. 20~30% of 20s level at age 70.

Female vs male: Women 50%+ from adrenals, men adrenals + testes.

Postmenopausal significance: Ovarian estrogen decline + DHEA decline overlap.

Supplement forms:

  • Oral DHEA (common supplement)
  • Topical DHEA (skin absorption)
  • Vaginal topical DHEA (prasterone, Intrarosa, FDA-approved)

Mechanism

Steroid precursor: DHEA converts to estradiol, testosterone. Conversion in target tissues.

Central nervous system: DHEA as neuroactive steroid. Psycho-emotional effects.

Immune regulation: Some data.

Bone health: Some data.

Muscle mass support: Some data, weak.

Indications and data

Vaginal atrophy (strongest data): Intrarosa (vaginal topical prasterone). FDA-approved postmenopausal moderate~severe vaginal dryness and dyspareunia.

Hyposexual disorder: Some data, mixed.

Depression symptoms (adrenal insufficiency): Some data.

Bone density: Some data.

Muscle mass: Some data in elderly.

Subjective wellbeing: Mixed data.

Adrenal insufficiency: Prescription indication.

Who fits

Postmenopausal vaginal symptoms: Intrarosa (vaginal topical) FDA-approved. First-line option.

Low DHEA-S measured populations: After physician evaluation.

Postmenopausal hormone support 60+: Greater meta-analysis effect.

Adrenal insufficiency: Prescription indication.

Symptomatic early menopause: 6-month trial option.

MHT-avoiding populations: Option (physician consultation essential).

Who should be careful

Hormone-sensitive cancers (breast, endometrial): Avoid. Hormone stimulation.

Ovarian cancer, prostate cancer: Avoid.

Pregnancy/breastfeeding: Avoid.

Male androgen sensitivity: Some side effects (acne, hair loss).

Female androgen side effects: Acne, facial hair, voice changes in some populations.

Drug interactions: Caution with antidepressants, statins, hormone medications.

Testing recommended: After baseline DHEA-S, estradiol, testosterone measurement.

Comparison to other menopause options

MHT (menopausal hormone therapy): Prescription. Strong data. Physician evaluation.

Phytoestrogens (isoflavones): Adjunct. Soy, red clover.

Black cohosh: Some hot flash data.

Low-dose SSRIs: Hot flash adjunct.

Gabapentin: Hot flash adjunct.

Saffron: Same period meta-analysis. Depression/anxiety adjunct.

DHEA is one of options. Match to target and data.

Daily guide

Step 1 — evaluation: Physician evaluation. DHEA-S, estradiol, testosterone, FSH, LH testing. Symptom assessment (menopause score, depression, sexual function).

Step 2 — foundation: Exercise (resistance + aerobic), sleep hygiene, diet (Mediterranean), stress management.

Step 3 — topical DHEA (vaginal symptoms): Intrarosa physician prescription. Strongest data.

Step 4 — oral DHEA: After physician evaluation. 50+ mg/day with 6-month trial assessment.

Step 5 — monitoring: Hormone, symptom re-assessment at 3~6 months.

Step 6 — other option integration: MHT, saffron, black cohosh, dietary etc. matrix.

DHEA is one tool of the menopause matrix. Strongest data for vaginal symptoms (Intrarosa). Other targets have mixed data. Physician evaluation and monitoring essential.